|
|
|
| Intermediate trend reversal confirmed | 02-NOV-09 |
|
| Prices collapsed in settlement week with the Nifty dropping 5.7 per cent to close at 4,711.7 points. The Sensex was down 5.5 per cent, closing at 15,896 points. The Defty was down 6.8 per cent with the dollar bouncing from over-sold levels. |
|
|
|
| USFDA tells Glenmark to withdraw drug | 15-OCT-09 |
|
| The US Food and Drug Administration (FDA) has directed Glenmark's US arm, Glenmark Generics Inc, and three other manufacturers to stop the marketing of unapproved codeine sulphate tablets in the US market. The drug is an old narcotics product widely used to treat pain. |
|
|
|
| Analysts' corner | 12-OCT-09 |
|
| In the next 18-24 months, Dr Reddy's could see news flow from a series of key products in the US – 'one off' (Starlix, Lotrel) as well as 'multi-year' (Prilosec OTC, Arixtra, Allegra D) limited competition opportunities. Some of these may manifest in the form of launches or settlements and exact timelines. |
|
|
|
|
|
|
| Doctors take management lessons for better pay | 04-OCT-09 |
|
| More doctors and healthcare professionals are joining management schools, turned away by the limited number of seats for a post-graduate course in medicine and the prospects of a better pay package after graduating from a B-school. |
|
|
|
| Dr Reddy's recalls 4 products from US | 01-OCT-09 |
|
| Dr Reddy's Laboratories has recalled some batches of four products from its key US market that were observed to contain some oversized tablets. |
|
|
|
| US patent lawsuit against Dr Reddy's | 16-SEP-09 |
|
| US-based drug discovery firm Albany Molecular Research, Inc (Amri) has filed two new patent infringement lawsuits in the US District Court in New Jersey against Dr. Reddy’s Laboratories Ltd., Dr. Reddy’s Laboratories, Inc. and Sandoz, Inc. |
|
|
|
| Which Price Index? | 17-AUG-09 |
|
| An accurate gauge for measuring a problem is the first requirement for finding a solution. A doctor who cannot read a patient’s pulse or temperature is unlikely to know what the problem is, and what to do about it. Ditto for the economy; monetary policy is likely to be off the mark if the measures for inflation, like the wholesale price index, are faulty and misleading. In recent weeks, the index has been reporting an absolute decline in prices. But the truth is that the index has become so out of date as to be practically useless; out of date because it measures (and gives weight to) the prices of products that have become less important to the economy, and ignores in relative terms those that have done the opposite. |
|
|
|
| Need a bigger push | 07-JUL-09 |
|
| THERE WERE NO big moves for the pharma sector but some of the announcements made were interesting. Increased government spending on healthcare is bound to have an impact in more ways than one. The reduction in customs duty on life-saving drugs and devices is a welcome move as it will improve affordability. |
|
|
|
| Big overseas buys dragged down profit last fiscal | 06-JUL-09 |
|
| The standalone business and revenue support from wholly owned subsidiaries having similar product lines rescued India Inc from posting sharp declines in profit in the year ended March 2009, when big-size overseas acquisitions began to bleed profusely. |
|
|
|
|
|
|
|
|
|
| Dr Reddy's to recruit 1,300 this yr | 16-JUN-09 |
|
| Global drug maker Dr Reddy’s Laboratories (DRL) is adding 1,300 people this year, including about 350 through campus recruitment, according to Prabir Kumar Jha, DRL’s senior vice-president and global chief (HR). |
|
|
|
| Dr Reddy's, GSK tie up for emerging mkts | 16-JUN-09 |
|
| Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories (DRL) has entered into a partnership with GlaxoSmithKline (GSK) to develop and market select products across emerging markets outside India. |
|
|
|
Content Guide
